Cardiovascular diseases in COPD patients with severe acute exacerbations: the prevalence and early identification of undiagnosed cardiac comorbidities- A prospective observational study

Cardiovascular diseases in COPD patients with severe acute exacerbations: the prevalence and early identification of undiagnosed cardiac comorbidities- A prospective observational study - CVD in COPD with severe exacerbations- the prevalence and early identification

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061753

Enrollment

104

Registered

2026-05-31

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases (CVD), including heart failure, ischemic heart disease, arrhythmias, and pulmonary hypertension, are common in patients with COPD and contribute substantially to morbidity and mortality. During acute exacerbations of COPD (AECOPD), cardiovascular events may be overlooked because their symptoms overlap with those of respiratory deterioration. Studies suggest that up to 40% of hospitalized AECOPD patients have unrecognized cardiac comorbidities. However, routine cardiovascu

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female outpatients aged from 40 to 90 years 2. Spirometry confirmed COPD patients (post-bronchodilation FEV1/FVC < 0.7) with medical record >= 1 year 3. Meet the criteria of severe AECOPD 4. Agree to attend the study and sign informed consent

Exclusion criteria

Exclusion criteria: 1. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease. 2. Hemodynamic instability requiring a life support machine, such as ECMO, IABP 3. Respiratory failure requiring intubation and mechanical ventilation 4. Coexisting medical conditions with a life expectancy of less than 1 year 5. Mental problem or unclear consciousness to obey medical treatment 6. Inability to ambulate or perform walking test

Design outcomes

Primary

Measure	Time frame
To evaluate whether a proactive comprehensive cardiac workup at the time of AECOPD is effective in detecting previously undiagnosed cardiac comorbidities and unrecognized concurrent CV events.	—

Secondary

Measure	Time frame
1. To evaluate the clinical value of EID during a spontaneous walking test, conducted in the recovery phase after acute symptom relief to detect undiagnosed cardiac comorbidities and unrecognized CV events. 2. To determine the prevalence of cardiac comorbidities in severe AECOPD patients (including newly diagnosed and existing diseases) 3. To investigate the proportion of coexisting CV events diagnosed by the proactive workup 4. To compare the changes of FeNO levels, symptom scores (CAT, mMRC), blood tests (CRP, CBC/DC, D-dimer), physiological parameters (both cardiac and pulmonary function), and EID among acute, recovery, and follow-up phases 5. To compare the major outcomes (annual rate of AECOPD, CV events, cardiopulmonary events) between baseline and follow-up phases 6. To discover the impact of CV comorbidities on the major outcomes (annual rate of AECOPD, CV events, cardiopulmonary events)	—

Measure

Time frame

1. To evaluate the clinical value of EID during a spontaneous walking test, conducted in the recovery phase after acute symptom relief to detect undiagnosed cardiac comorbidities and unrecognized CV events. 2. To determine the prevalence of cardiac comorbidities in severe AECOPD patients (including newly diagnosed and existing diseases) 3. To investigate the proportion of coexisting CV events diagnosed by the proactive workup 4. To compare the changes of FeNO levels, symptom scores (CAT, mMRC), blood tests (CRP, CBC/DC, D-dimer), physiological parameters (both cardiac and pulmonary function), and EID among acute, recovery, and follow-up phases 5. To compare the major outcomes (annual rate of AECOPD, CV events, cardiopulmonary events) between baseline and follow-up phases 6. To discover the impact of CV comorbidities on the major outcomes (annual rate of AECOPD, CV events, cardiopulmonary events)

—

Countries

Asia(except Japan)

Contacts

Public ContactKang-Cheng Su

Taipei Veterans General Hospital Department of Chest Medicine

kcsu@vghtpe.gov.tw886-2-28712121-3152

Outcome results